Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Fortrea Holdings Inc. - Common Stock (NQ:FTRE)

4.595 +0.145 (+3.26%)
Streaming Delayed Price Updated: 9:51 AM EDT, May 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Fortrea Holdings Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
3 Value Stocks in Hot Water
Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few... 
Via StockStory
Beyond The Numbers: 6 Analysts Discuss Fortrea Holdings Stock
Via Benzinga
Securities Fraud Investigation Into Fortrea Holdings Inc. (FTRE) Continues – Investors Who Lost Money Urged to Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
From Glancy Prongay & Murray LLP
Via Business Wire
Fortrea Holdings Inc. (FTRE) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
From Law Offices of Howard G. Smith
Via Business Wire
Earnings Scheduled For May 12, 2025
Via Benzinga
Securities Fraud Investigation Into Fortrea Holdings Inc. (FTRE) Continues – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
From The Law Offices of Frank R. Cruz
Via Business Wire
Why Fortrea (FTRE) Stock Is Falling Today
Shares of clinical research company Fortrea Holdings (NASDAQ:FTRE) fell 14.3% in the afternoon session after the company reported first quarter 2025 earnings as the news of the CEO stepping down... 
Via StockStory
Fortrea’s (NASDAQ:FTRE) Q1: Strong Sales, Full-Year Outlook Slightly Exceeds Expectations
Clinical research company Fortrea Holdings (NASDAQ:FTRE) beat Wall Street’s revenue expectations in Q1 CY2025, but sales fell by 1.6% year on year to $651.3 million. The company’s full-year revenue... 
Via StockStory
Fortrea Reports First Quarter 2025 Results
From Fortrea Holdings Inc
Via GlobeNewswire
Fortrea Announces CEO Stepping Down
Peter M. Neupert, Fortrea’s Lead Independent Director, will serve as Interim CEO as Thomas Pike steps down 
From Fortrea Holdings Inc
Via GlobeNewswire
Earnings To Watch: Fortrea (FTRE) Reports Q1 Results Tomorrow
Clinical research company Fortrea Holdings (NASDAQ:FTRE) will be reporting results tomorrow before market open. Here’s what to expect. 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
3 Volatile Stocks Skating on Thin Ice
Volatility cuts both ways - while it creates opportunities, it also increases risk, making sharp declines just as likely as big gains. This unpredictability can shake out even the most experienced... 
Via StockStory
Fortrea Named a Leader in Everest Group’s Pharmacovigilance Operations PEAK Matrix® Assessment 2025
Recognized in both pre-and post-approval pharmacovigilance operations 
From Fortrea Holdings Inc
Via GlobeNewswire
3 Small-Cap Stocks Skating on Thin Ice
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside... 
Via StockStory
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fortrea Holdings Inc. - FTRE
From Pomerantz LLP
Via GlobeNewswire
1 Cash-Producing Stock That Stand Out and 2 to Be Wary Of
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak... 
Via StockStory
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fortrea Holdings Inc. - FTRE
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fortrea Holdings Inc. - FTRE
From Pomerantz LLP
Via GlobeNewswire
Fortrea Announces Date for First Quarter 2025 Financial Results and Conference Call
From Fortrea Holdings Inc
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fortrea Holdings Inc. - FTRE
From Pomerantz LLP
Via GlobeNewswire
1 Oversold Stock Primed to Rebound and 2 to Approach with Caution
Hitting a new 52-week low can be a pivotal moment for any stock. These floors often mark either the beginning of a turnaround story or confirmation that a company faces serious headwinds. 
Via StockStory
Demystifying Fortrea Holdings: Insights From 4 Analyst Reviews
Via Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Fortrea Holdings Inc. - FTRE
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fortrea Holdings Inc. - FTRE
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fortrea Holdings Inc. - FTRE
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fortrea Holdings Inc. - FTRE
From Pomerantz LLP
Via GlobeNewswire
Winners And Losers Of Q4: IQVIA (NYSE:IQV) Vs The Rest Of The Drug Development Inputs & Services Stocks
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how IQVIA (NYSE:IQV) and the rest... 
Via StockStory
Bragar Eagel & Squire, P.C. Is Investigating Fortrea and Ibotta and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Unpacking Q4 Earnings: West Pharmaceutical Services (NYSE:WST) In The Context Of Other Drug Development Inputs & Services Stocks
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at West Pharmaceutical Services (NYSE:WST) and its peers. 
Via StockStory
Drug Development Inputs & Services Stocks Q4 In Review: Medpace (NASDAQ:MEDP) Vs Peers
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the drug development inputs & services stocks, including Medpace (NASDAQ:MEDP) and its peers. 
Via StockStory
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.